KIT and coronary artery disorder: In a recent phase I clinical trial (SCIPIO), c-kit+ CPCs isolated from patients with ischemic cardiomyopathy significantly improved cardiac function and structure as well as functional capacity and quality of life when transplanted back into the failing hearts via intracoronary injection [15], clearly demonstrating the utility of these cells in the treatment of ischemic heart diseases.